Idiosyncratic Blog

Unleash Your Quirky Side: Idiosyncratic Blog

[Research Spotlight] Miaoling Plasmid Supports Research on Multi-TAC Multimodal Immunotherapy

4 min read

The complexity and substantial heterogeneity of the tumor immune microenvironment (TIME) remain major obstacles to the effectiveness of immunotherapy for solid tumors. Conventional combination therapies often face challenges such as overlapping toxicities and a lack of effective therapeutic synergy. A research team led by Professors Peng Chen and Jianzhong Xi from Peking University published a landmark study in the prestigious journal Cell, titled "Multimodal Targeting Chimeras Enable Integrated Immunotherapy Leveraging Tumor-Immune Microenvironment" (IF = 45.6).

Miaoling Biotechnology provided a key lentiviral overexpression plasmid for this study, supporting the research team's development of cellular models to evaluate the therapeutic potential of multimodal targeting chimeras (Multi-TACs).

The researchers developed an innovative trivalent orthogonal linker (T-Linker) technology that works much like a modular building system. It enables the precise and programmable integration of three functional components—a tumor-targeting module, an immune cell-recruiting module, and an immune-stimulating module—into a single molecular construct. The resulting multimodal targeting chimeras (Multi-TACs) enable coordinated recruitment and activation of multiple immune cell populations within the tumor microenvironment.

T-Linker Technology: Overcoming the Limitations of Conventional Bispecific Antibodies

To integrate multiple therapeutic modules into a single construct, the research team designed a T-Linker scaffold containing three mutually orthogonal reactive handles. This platform enables the efficient and stable conjugation of three distinct functional components, including antibodies, peptides, and small molecules. It also demonstrated favorable biocompatibility in vivo, without evident signs of toxicity under the tested conditions.

Building on this platform, the researchers successfully developed EGFR-CD3-PDL1 Multi-TAC, a construct with three complementary functions:

  • Tumor targeting: Anti-EGFR binds to EGFR-expressing tumor cells.
  • T-cell recruitment: Anti-CD3 engages T cells.
  • Dendritic cell (DC) engagement: Anti-PD-L1 targets PD-L1-expressing dendritic cells.

A Dual-Cell Strategy: Physical Bridging of T Cells and DCs Enhances Antitumor Immunity

This design enables the physical co-engagement of T cells and dendritic cells on the surface of target tumor cells, forming a tightly associated ternary complex (T:DC::tumor).

In vitro validation: EGFR-CD3-PDL1 Multi-TAC not only directly activated T cells to release granzyme B and IFN-γ, promoting tumor cell killing, but also significantly enhanced DC maturation, as indicated by increased CD83 and CD86 expression. It further promoted the release of inflammatory cytokines, including IL-12 and IL-1β.

More importantly, the construct enhanced the antigen-presenting capacity of DCs, thereby stimulating antigen-specific T-cell immune responses.

In vivo validation: Across multiple humanized mouse models, including peripheral blood mononuclear cell (PBMC)- and hematopoietic stem cell (HSC)-based models, as well as immunocompetent transgenic mouse models, Multi-TAC demonstrated enhanced tumor retention and potent tumor growth inhibition. Treatment also significantly increased the infiltration of T cells into tumors and the activation of both T cells and DCs.

Clinical Translation Potential and the Expandability of the Platform

To assess its potential for clinical translation, the research team evaluated the platform using patient-derived tumor cell cluster (PTC) models.

Across 44 clinical samples representing six cancer types, including non-small cell lung cancer (NSCLC), ovarian cancer, bladder cancer, and colorectal cancer, EGFR-CD3-PDL1 Multi-TAC achieved an overall response rate of 75%. The response rate reached 87% in NSCLC samples, outperforming pembrolizumab (Keytruda), a first-line PD-1 inhibitor, in the reported comparison.

The platform also offers considerable flexibility for further development. The researchers successfully generated additional Multi-TAC constructs, including:

  • EGFR-CD3-CD16 Multi-TAC: Designed to recruit natural killer (NK) cells.
  • HER2-CD3-(IMDQ) Multi-TAC: Designed to engage myeloid cells.

These findings highlight the considerable potential of the T-Linker platform for integrating multiple immune-targeting and immune-activating functions into a single therapeutic strategy.

Miaoling's Contribution: Supporting Advanced Immunotherapy Research

Reliable gene delivery tools are essential for engineering cellular models and validating complex multimodal immunotherapy strategies.

Miaoling Biotechnology (Wuhan, China) provided the research team with a lentiviral overexpression plasmid encoding human EGFR with a FLAG tag (Cat. No. P7777). This plasmid played an important role in generating human EGFR-overexpressing mouse tumor cells and establishing the tumor models used for subsequent in vivo validation.

The Miaoling plasmid used in this study is detailed below:

Catalog No.

Product Name

Vector Features and Application in This Study

P7777

pLVX-EnCMV-EGFR(human)-FLAG-PGK-Puro-WPRE

Lentiviral overexpression vector featuring an EnCMV promoter driving human EGFR expression, a FLAG tag, a PGK promoter driving puromycin (Puro) resistance, and a WPRE regulatory element. In this study, the plasmid was used to transduce MC38 cells, followed by selection of a stable cell population with high human EGFR expression. These engineered cells were subsequently used to establish an MC38hEGFR+OVA+ syngeneic tumor model in mice, enabling targeted recognition by Multi-TAC.

High-quality expression vectors are fundamental to successful experimental outcomes. Miaoling Biotechnology provides a comprehensive range of standardized plasmids for gene overexpression, gene silencing, and epitope tagging, supported by established lentiviral packaging capabilities and an extensive collection of vector elements.

Whether researchers are engineering complex cell lines, developing animal models, or investigating emerging molecular mechanisms, Miaoling is committed to providing reliable, efficient, and integrated custom services to support research from fundamental discovery toward clinical translation.

All research images are reproduced from the original publication.

Original Publication: https://doi.org/10.1016/j.cell.2024.10.016

https://www.miaolingbio.net
Wuhan MiaoLing Biotechnology Co., Ltd.

About Author

Leave a Reply

Your email address will not be published. Required fields are marked *